An experimental weight-loss drug, eloralintide, has shown significant weight loss results in clinical trials, potentially offering a new treatment option for obesity, according to a recent study published in The Lancet. The once-weekly injectable medication, developed by Eli Lilly, demonstrated up to 20% body weight reduction in 263 adults who were overweight or obese but not diabetic over 48 weeks. The placebo group experienced only a 0.4% weight loss during the same period. The drug was generally well-tolerated by participants, with mild to moderate gastrointestinal symptoms and fatigue noted as the primary side effects.
Lead study author, Dr. Liana K. Billings of Endeavor Health, highlighted that the weight loss observed in the trial is